Definition
Menopause is the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. It is a natural biological process that marks the end of a woman's reproductive years. The diagnosis is made retrospectively after 12 consecutive months of amenorrhoea without any other pathological or physiological cause.
Epidemiology
-
The average age of menopause is 50–52 years.
-
It usually occurs between ages 45 and 55.
-
Premature menopause: before age 40.
-
Early menopause: between ages 40 and 45.
Pathophysiology
Menopause occurs due to depletion of ovarian follicles and reduced estrogen and progesterone production. This leads to:
-
Elevated follicle-stimulating hormone (FSH) and luteinising hormone (LH) levels due to loss of negative feedback.
-
Decreased estrogen levels causing vasomotor symptoms, urogenital atrophy, and bone loss.
Stages of Menopause
-
Perimenopause
-
Transitional period with irregular cycles and onset of menopausal symptoms.
-
-
Menopause
-
Final menstrual period, confirmed after 12 months without menstruation.
-
-
Postmenopause
-
Time after menopause, with continued low estrogen levels and increased long-term health risks.
-
Symptoms
Vasomotor Symptoms
-
Hot flushes (sudden feelings of heat, flushing, sweating).
-
Night sweats.
Genitourinary Symptoms
-
Vaginal dryness, itching, burning.
-
Dyspareunia (painful intercourse).
-
Recurrent urinary tract infections.
-
Urinary urgency and frequency.
Psychological Symptoms
-
Mood swings, irritability.
-
Anxiety, depression.
-
Poor concentration, memory changes.
Other Symptoms
-
Sleep disturbances.
-
Joint and muscle aches.
-
Skin and hair changes.
Complications
-
Osteoporosis: due to reduced bone mineral density.
-
Cardiovascular disease: loss of estrogen increases risk.
-
Urogenital atrophy: progressive thinning and inflammation of vaginal and urinary tract tissues.
Diagnosis
-
Clinical diagnosis: based on history and 12 months of amenorrhoea in women over 45 years.
-
Laboratory tests: not routinely needed, but FSH may be measured in women <45 years or when diagnosis is uncertain (FSH usually >40 IU/L).
Management
1. Lifestyle Modifications
-
Maintain healthy weight.
-
Regular exercise (weight-bearing for bone health).
-
Balanced diet rich in calcium and vitamin D.
-
Avoid triggers for hot flushes (alcohol, caffeine, spicy foods).
-
Smoking cessation.
2. Pharmacological Treatment
Hormone Replacement Therapy (HRT)
-
Most effective treatment for vasomotor symptoms.
-
Choice depends on presence of uterus:
-
With uterus: Combined estrogen + progestogen to prevent endometrial hyperplasia.
-
Without uterus: Estrogen alone.
-
Common HRT Options and Doses
-
Estradiol (oral): 1–2 mg once daily.
-
Conjugated estrogens (oral): 0.3–0.625 mg once daily.
-
Estradiol (transdermal patch): 25–100 micrograms/day, changed twice weekly.
-
Progesterone (micronised, oral): 100 mg daily or 200 mg nightly for 12–14 days each month.
-
Medroxyprogesterone acetate: 5–10 mg daily for 12–14 days/month.
Non-hormonal Options for Vasomotor Symptoms (for women who cannot take HRT)
-
Venlafaxine: 37.5–75 mg daily.
-
Paroxetine: 10–20 mg daily.
-
Gabapentin: 300 mg at night, increasing to 300 mg three times daily as tolerated.
-
Clonidine: 25–50 micrograms twice daily.
3. Urogenital Symptoms
Local Estrogen Therapy
-
Estriol vaginal cream: 0.5 mg nightly for 2–3 weeks, then twice weekly.
-
Estradiol vaginal tablet: 10 micrograms daily for 2 weeks, then twice weekly.
-
Estradiol vaginal ring: releases 7.5 micrograms/day for 90 days.
4. Osteoporosis Prevention and Treatment
-
Calcium: 1000–1200 mg/day.
-
Vitamin D: 800–1000 IU/day.
-
Bisphosphonates (if indicated): e.g., Alendronic acid 70 mg once weekly.
-
Selective estrogen receptor modulators (SERMs): e.g., Raloxifene 60 mg daily.
Contraindications to HRT
-
History of breast or endometrial cancer.
-
Active or recent thromboembolic disease.
-
Undiagnosed vaginal bleeding.
-
Severe liver disease.
Monitoring
-
Annual review of symptom control, side effects, and risk factors.
-
Regular breast screening.
-
Blood pressure and cardiovascular risk assessment.
No comments:
Post a Comment